Abbvie’s Patents on Humira Challenged by Alvotech

May 11, 2021, 2:59 PM

Alvotech hf filed a lawsuit seeking to invalidate what it calls “dubious” patents on AbbVie’s Humira and accusing the drugmaker of engaging in a widespread campaign to keep biosimilars of the anti-inflammatory drug off the U.S. market.

  • AbbVie has “an outrageous number of patents of dubious validity” and anyone who wants to make a copy of the medicine is “threatened with crushing, ruinous litigation on these patents,” Iceland-based Alvotech said in the complaint filed in federal court in Alexandria, Virginia
    • The lawsuit only cites four patents, claiming they are invalid and unenforceable in part because of misuse on AbbVie’s ...

To read the full article log in. To learn more about a subscription click here.